Barely Significant
← all excerpts

Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis.

Ann Hematol · 2025 · PMC12672616 · PMID 41203978

Europe PMCDOI
1
hedged sentence
0.3900
closest p · 7.8× alpha
0.3900
boldest claim

The sentences

a slight trendp = 0.39not close (p > 0.1)
Although high t(11;14) patients demonstrated a slight trend toward superior EFS (Fig. 3 b), neither log-rank test for overall survival curve differences ( p = 0.39) nor Cox proportional hazards model (HR = 2.05, 95% CI: 0.37–11.2, p = 0.41) were statistically significant.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.